BioMedNewsBreaks

TuesdayJan 26, 2021 11:36 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Addition of Two Clinical Trial Sites for MS1819 Phase 2b OPTION 2 Extension Study

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has added two clinical trial sites for the extension arm of its MS1819 Phase 2b OPTION 2 study. The study is investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). The additional sites were added in Poland; Europe was selected to reduce potential patient-enrollment delays caused by the COVID-19 pandemic. The two sites in Poland and the active clinical trial sites in the United States have already begun enrolling patients. AzurRX expects  topline data to be available…

Continue Reading

FridayJan 22, 2021 12:49 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees…

Continue Reading

ThursdayJan 21, 2021 11:40 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces Plans to Develop Micro Brain E-Tattoo Device for Growing Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has begun development of a brain E-Tattoo device. The company announced that the innovative product will feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The electrodes will connect to the micro EEG, which will be located behind the ear and which processes signals from the sensors and transfers the data to a cloud application. The proprietary offering is designed to provide continuous monitoring for data collection in patients with epilepsy and Alzheimer’s as well as patients who have suffered a stroke or…

Continue Reading

ThursdayJan 21, 2021 11:00 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Beginning of MS1819 Extension Study with Initial Dosing of Two Patients

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The OPTION 2 extension phase design, which was recently announced by AzurRx, is designed to evaluate patients…

Continue Reading

ThursdayJan 21, 2021 10:28 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light on recent advancements concerning its upcoming clinical trials for the treatment of non-small cell lung cancer. The company will present at 12:25 PM EST on Thursday, January 28th. The presentation will be available for replay on the company’s website and www.MoneyShow.com. To register for the…

Continue Reading

WednesdayJan 20, 2021 10:46 am

BioMedNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Collaboration to Evaluate Feasibility of Ultra Shear Technology Platform to Improve Effectiveness of SinuSys Lead Product Candidate

Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI's innovative Ultra Shear Technology(TM) ("UST") platform to strengthen the effectiveness of SinuSys Corp's lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI's UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later this year. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology services to the worldwide biotechnology, biotherapeutics and other industries. SinuSys Corporation is a medical device…

Continue Reading

WednesdayJan 20, 2021 10:46 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Lab Test Results of Patented Biopesticide Achieve 100% Control of Root-Rot Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced successful test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores ("Aphanomyces"). The tests, conducted via an independent third-party facility, achieved 100% control of the root-rot disease Aphanomyces zoospores at economic application rates within 24 hours; Aphanomyces is a soil-borne disease that destroys key plant-based protein crops such as peas, lentils and legumes; current treatments are unable to control the disease. MustGrow next plans to test its proprietary biopesticide in larger-scale greenhouse and field settings. The company’s safe…

Continue Reading

WednesdayJan 20, 2021 10:22 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Hires IR Firm Torrey Hills Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced its engagement of Rancho Santa Fe, California-based investor relations firm San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital") to deliver market awareness and investor relations services to IMEXF, subject to acceptance by the Canadian Securities Exchange ("CSE"). The move enables the company to cultivate an informed investor audience in both the U.S. and Canadian marketplaces. The company has engaged the firm at a rate of US$7,000 per month. Following the initial term…

Continue Reading

WednesdayJan 20, 2021 9:38 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategy for New Year; Outlines Expected Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released its business strategy and expected milestones for 2021. The company noted that in the coming year it anticipates commercialization of its proprietary rapid COVID-19 PCR (“PCR”) test as well as clinical validation of is exclusive transdermal and sublingual drug formulations; XPhyto is also planning on psychedelic API production, drug formulation and clinical integration in 2021. The announcement observed that XPhyto is on the cusp of transformational change as product development programs advance from the laboratory to the clinic. The company…

Continue Reading

WednesdayJan 20, 2021 9:14 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Executive Chairman Quoted in Elite Healthcare Article Noting How the Pandemic Might Impact Healthcare in 2021

Brain Scientific (OTCQB: BRSF) co-founder and executive chairman Boris Goldstein was quoted in a recent Elite Healthcare article titled “A Look at 2021 Healthcare with the Pandemic.” The article quoted a variety of clinicians and industry professionals who consider themselves futurists and who specialize in exploring predictions and possibilities based on present trends. The article discussed health care in 2021 from a variety of standpoints including individualized healthcare, technology timelines, conducting clinical trials, emerging emergency response, pediatric parameters, and facility design and work flows. Some trends were obvious, such as the dramatic growth of telehealth and various Internet of Medical Things;…

Continue Reading